Bellmunt Risk Score for Survival Prediction in Gastroenteropancreatic Neuroendocrine Tumors with [177Lu]Lu-DOTA-TATE Therapy – preliminary results
Nuklearmedizin - NuclearMedicine · 01.04.2026 · 65 (02) · 175
DOI: 10.1055/s-0046-1818375 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2026. Verfasst von E Dema und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Ziel/Aim: The Peptide-Radio-Receptor Therapy (PRRT) with [ 177 Lu]Lu-DOTA-TATE has been proven to be an effective therapy option for metastatic Neuroendocrine Tumors (NETs). However, due to the observed differences in treatment outcomes among patients, this study sought to assess whether the Bellmunt Risk Score (BRS) could serve as a predictive tool in gastroenteropancreatic (GEP) NETs treated with PRRT. Methodik/Methods: This retrospective analysis included 232 GEP-NET patients (125=male; 107=female; mean age 66.9±11.7) treated with at least one cycle of PRRT. The BRS was applied by assigning one point for each of the following factors: ECOG performance status>0, hemoglobin level 30mg/L as a risk factor, while the modified BRS (mBRS) integrated a semi-quantitative assessment of ECOG performance status. To investigate overall survival (OS), Kaplan–Meier survival analyses were performed, and differences between groups were assessed using the log-rank test. Ergebnisse/Results: The median OS was 7.9 and 6.3 years for patients with scores 1 and 2, respectively (log-rank test for trend, p=0.046), although pairwise comparisons between individual score groups were not significant. The mBRS was also associated with OS (p=0.002); patients with a score of 1 showed significantly longer survival than those with scores of 3 (HR 0.08, 95% CI 0.02–0,31, p
Zitieren
APA
Dema, E., Auernhammer, C., Cyran, C., Sheikh, G., Klimek, K., Widjaja, L., Werner, R., & Siegmund, S. (2026). Bellmunt Risk Score for Survival Prediction in Gastroenteropancreatic Neuroendocrine Tumors with [177Lu]Lu-DOTA-TATE Therapy – preliminary results. Nuklearmedizin - NuclearMedicine, 65(02), 175. https://doi.org/10.1055/s-0046-1818375
Vancouver
Dema E, Auernhammer C, Cyran C, Sheikh G, Klimek K, Widjaja L, et al. Bellmunt Risk Score for Survival Prediction in Gastroenteropancreatic Neuroendocrine Tumors with [177Lu]Lu-DOTA-TATE Therapy – preliminary results. Nuklearmedizin - NuclearMedicine. 2026;65(02):175. doi:10.1055/s-0046-1818375
BibTeX
@article{Dema2026,
author = {Dema, E and Auernhammer, C and Cyran, C and Sheikh, G and Klimek, K and Widjaja, L and Werner, R and Siegmund, S},
title = {Bellmunt Risk Score for Survival Prediction in Gastroenteropancreatic Neuroendocrine Tumors with [177Lu]Lu-DOTA-TATE Therapy – preliminary results},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2026},
volume = {65},
number = {02},
pages = {175},
doi = {10.1055/s-0046-1818375}
}
EUVIMED